Table 5 Adjusted comparison of treatment discontinuation at 12 months in patients newly treated with antifibrotic drugs
HR | 95% CI | p-value | |
|---|---|---|---|
Treatment | |||
Pirfenidone | 1.00 | – | – |
Nintedanib | 0.72 | 0.60–0.86 | < 0.01 |
Age at treatment initiation | 1.03 | 1.01–1.04 | < 0.01 |
Sex | |||
Male | 1.00 | – | – |
Female | 1.37 | 1.15–1.63 | < 0.01 |
Year of antifibrotic treatment initiation | |||
2015 | 1.00 | – | – |
2016 | 1.15 | 0.96–1.37 | 0.12 |
Time from IPF diagnosis to treatment initiation | |||
≤ 1 month | 1.00 | – | – |
1–12 months | 0.86 | 0.70–1.06 | 0.15 |
> 12 months | 1.10 | 0.90–1.34 | 0.35 |
Number of acute respiratory-related hospital admissions during the year prior to treatment initiation | |||
0 | 1.00 | – | – |
1 | 0.83 | 0.68–1.00 | 0.06 |
2 or more | 0.80 | 0.58–1.11 | 0.18 |
Number of outpatient visits to a hospital physician during the year prior to treatment initiation | |||
0 | 1.00 | – | – |
1 or 2 | 0.82 | 0.62–1.07 | 0.14 |
3 or 4 | 0.99 | 0.75–1.30 | 0.94 |
5 or more | 0.91 | 0.69–1.20 | 0.52 |
Charlson comorbidity score | |||
1–2 | 1.00 | – | – |
3–4 | 1.03 | 0.78–1.36 | 0.83 |
5 or more | 0.93 | 0.67–1.29 | 0.67 |
Use of supplemental oxygen at baseline | |||
Yes | 1.21 | 1.00–1.45 | 0.05 |